Massachusetts Biologic Laboratories
Division of University of Massachusetts
Latest From Massachusetts Biologic Laboratories
Adaptive designs and studies at multiple infection sites are among industry suggestions to the agency as possible new approaches to developing drugs to fight bacterial infections.
The concept of multiple antibodies in one mixture to treat disease, once solely the provenance of serum-derived polyclonal therapies, is enticing a new wave of developers. With a technological head start and a vault full of private backing, Danish firm Symphogen is the field’s pioneer – and hopes to avoid the arrows.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.